$FGEN
FIBROGEN INC

2024 Q4 Form 10-Q Financial Statement

#000095017024125388 Filed on November 12, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $46.33M
YoY Change 15.45%
Cost Of Revenue $5.295M
YoY Change 24.79%
Gross Profit $41.04M
YoY Change 14.34%
Gross Profit Margin 88.57%
Selling, General & Admin $17.55M
YoY Change -31.36%
% of Gross Profit 42.77%
Research & Development $21.71M
YoY Change -64.53%
% of Gross Profit 52.9%
Depreciation & Amortization $739.0K
YoY Change -68.95%
% of Gross Profit 1.8%
Operating Expenses $39.26M
YoY Change -54.75%
Operating Profit -$16.78M
YoY Change -73.57%
Interest Expense $4.994M
YoY Change -0.56%
% of Operating Profit
Other Income/Expense, Net $3.802M
YoY Change -11.5%
Pretax Income -$17.97M
YoY Change -72.01%
Income Tax $12.00K
% Of Pretax Income
Net Earnings -$17.08M
YoY Change -73.14%
Net Earnings / Revenue -36.87%
Basic Earnings Per Share -$0.17
Diluted Earnings Per Share -$0.17
COMMON SHARES
Basic Shares Outstanding 100.8M 100.4M
Diluted Shares Outstanding 100.5M

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $131.0M
YoY Change -47.87%
Cash & Equivalents $131.0M
Short-Term Investments $0.00
Other Short-Term Assets $3.193M
YoY Change -92.1%
Inventory $23.94M
Prepaid Expenses $3.062M
Receivables $29.03M
Other Receivables $44.03M
Total Short-Term Assets $244.5M
YoY Change -32.84%
LONG-TERM ASSETS
Property, Plant & Equipment $7.603M
YoY Change -47.61%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $5.806M
YoY Change 28.05%
Other Assets $2.732M
YoY Change -30.87%
Total Long-Term Assets $19.89M
YoY Change -79.35%
TOTAL ASSETS
Total Short-Term Assets $244.5M
Total Long-Term Assets $19.89M
Total Assets $264.4M
YoY Change -42.57%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $9.238M
YoY Change -51.94%
Accrued Expenses $151.1M
YoY Change -11.61%
Deferred Revenue $28.86M
YoY Change 293.97%
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $190.5M
YoY Change -9.02%
LONG-TERM LIABILITIES
Long-Term Debt $90.98M
YoY Change 2.68%
Other Long-Term Liabilities $837.0K
YoY Change -80.33%
Total Long-Term Liabilities $837.0K
YoY Change -80.33%
TOTAL LIABILITIES
Total Short-Term Liabilities $190.5M
Total Long-Term Liabilities $837.0K
Total Liabilities $466.1M
YoY Change -19.02%
SHAREHOLDERS EQUITY
Retained Earnings -$1.907B
YoY Change 6.82%
Common Stock $1.008M
YoY Change 2.54%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$243.7M
YoY Change
Total Liabilities & Shareholders Equity $264.4M
YoY Change -42.57%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$17.08M
YoY Change -73.14%
Depreciation, Depletion And Amortization $739.0K
YoY Change -68.95%
Cash From Operating Activities -$8.376M
YoY Change -90.09%
INVESTING ACTIVITIES
Capital Expenditures $82.00K
YoY Change -88.12%
Acquisitions
YoY Change
Other Investing Activities $837.0K
YoY Change -98.48%
Cash From Investing Activities $755.0K
YoY Change -98.61%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -127.0K
YoY Change 535.0%
NET CHANGE
Cash From Operating Activities -8.376M
Cash From Investing Activities 755.0K
Cash From Financing Activities -127.0K
Net Change In Cash -7.748M
YoY Change -74.46%
FREE CASH FLOW
Cash From Operating Activities -$8.376M
Capital Expenditures $82.00K
Free Cash Flow -$8.458M
YoY Change -90.08%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0000921299
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2024Q3 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2024#ProductMember
CY2023Q3 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2024#ProductMember
us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2024#ProductMember
us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2024#ProductMember
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36740
dei Entity Registrant Name
EntityRegistrantName
FIBROGEN, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
77-0357827
dei Entity Address Address Line1
EntityAddressAddressLine1
350 Bay Street
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 100, #6009
dei Entity Address City Or Town
EntityAddressCityOrTown
San Francisco
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94158
dei City Area Code
CityAreaCode
415
dei Local Phone Number
LocalPhoneNumber
978-1200
dei Security12b Title
Security12bTitle
Common Stock, $0.01 par value
dei Trading Symbol
TradingSymbol
FGEN
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
100770153
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
131003000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
113688000
CY2024Q3 us-gaap Short Term Investments
ShortTermInvestments
0
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
121898000
CY2024Q3 fgen Accounts Receivable Net Current Related Parties
AccountsReceivableNetCurrentRelatedParties
15534000
CY2023Q4 fgen Accounts Receivable Net Current Related Parties
AccountsReceivableNetCurrentRelatedParties
6079000
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
29030000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
12553000
CY2024Q3 us-gaap Inventory Net
InventoryNet
23937000
CY2023Q4 us-gaap Inventory Net
InventoryNet
41565000
CY2024Q3 fgen Prepaid Expense And Other Assets Current Related Party
PrepaidExpenseAndOtherAssetsCurrentRelatedParty
24785000
CY2023Q4 fgen Prepaid Expense And Other Assets Current Related Party
PrepaidExpenseAndOtherAssetsCurrentRelatedParty
0
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
60559000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
41855000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
244529000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
331559000
CY2024Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1658000
CY2023Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1658000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7603000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13126000
CY2024Q3 us-gaap Equity Method Investments
EquityMethodInvestments
5806000
CY2023Q4 us-gaap Equity Method Investments
EquityMethodInvestments
5290000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2093000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
68093000
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2732000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3803000
CY2024Q3 us-gaap Assets
Assets
264421000
CY2023Q4 us-gaap Assets
Assets
423529000
CY2024Q3 fgen Accounts Payable Related Party Current
AccountsPayableRelatedPartyCurrent
2000
CY2023Q4 fgen Accounts Payable Related Party Current
AccountsPayableRelatedPartyCurrent
0
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
9238000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
17960000
CY2024Q3 fgen Other Liabilities Current Due To Related Parties
OtherLiabilitiesCurrentDueToRelatedParties
12592000
CY2023Q4 fgen Other Liabilities Current Due To Related Parties
OtherLiabilitiesCurrentDueToRelatedParties
39814000
CY2024Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
151141000
CY2023Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
172891000
CY2024Q3 fgen Due To Related Parties Deferred Revenue Current
DueToRelatedPartiesDeferredRevenueCurrent
6723000
CY2023Q4 fgen Due To Related Parties Deferred Revenue Current
DueToRelatedPartiesDeferredRevenueCurrent
7220000
CY2024Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
28858000
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
12740000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1293000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
14077000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
190530000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
217668000
CY2024Q3 fgen Accrued Product Development Costs
AccruedProductDevelopmentCosts
18199000
CY2023Q4 fgen Accrued Product Development Costs
AccruedProductDevelopmentCosts
17763000
CY2024Q3 fgen Due To Related Parties Deferred Revenue Noncurrent
DueToRelatedPartiesDeferredRevenueNoncurrent
1388000
CY2023Q4 fgen Due To Related Parties Deferred Revenue Noncurrent
DueToRelatedPartiesDeferredRevenueNoncurrent
9705000
CY2024Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
126219000
CY2023Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
157555000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
707000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
66537000
CY2024Q3 us-gaap Secured Long Term Debt
SecuredLongTermDebt
72779000
CY2023Q4 us-gaap Secured Long Term Debt
SecuredLongTermDebt
71934000
CY2024Q3 fgen Liability Related To Sale Of Future Revenues Non Current
LiabilityRelatedToSaleOfFutureRevenuesNonCurrent
56850000
CY2023Q4 fgen Liability Related To Sale Of Future Revenues Non Current
LiabilityRelatedToSaleOfFutureRevenuesNonCurrent
51413000
CY2024Q3 fgen Other Liabilities Noncurrent Due To Related Parties
OtherLiabilitiesNoncurrentDueToRelatedParties
559000
CY2023Q4 fgen Other Liabilities Noncurrent Due To Related Parties
OtherLiabilitiesNoncurrentDueToRelatedParties
656000
CY2024Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
837000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2858000
CY2024Q3 us-gaap Liabilities
Liabilities
466121000
CY2023Q4 us-gaap Liabilities
Liabilities
585728000
CY2024Q3 us-gaap Redeemable Noncontrolling Interest Equity Carrying Amount
RedeemableNoncontrollingInterestEquityCarryingAmount
21480000
CY2023Q4 us-gaap Redeemable Noncontrolling Interest Equity Carrying Amount
RedeemableNoncontrollingInterestEquityCarryingAmount
21480000
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
125000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
125000000
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
225000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
225000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
100770000
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
100770000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
98770000
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
98770000
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
1008000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
988000
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1668434000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1643641000
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-5628000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-6875000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1907481000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1841920000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-243667000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-204166000
CY2024Q3 us-gaap Nonredeemable Noncontrolling Interest
NonredeemableNoncontrollingInterest
20487000
CY2023Q4 us-gaap Nonredeemable Noncontrolling Interest
NonredeemableNoncontrollingInterest
20487000
CY2024Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-223180000
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-183679000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
264421000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
423529000
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
46333000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
40134000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
152877000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
120614000
CY2024Q3 us-gaap Cost Of Revenue
CostOfRevenue
5295000
CY2023Q3 us-gaap Cost Of Revenue
CostOfRevenue
4243000
us-gaap Cost Of Revenue
CostOfRevenue
36227000
us-gaap Cost Of Revenue
CostOfRevenue
13441000
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
21708000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
61194000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
94206000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
231158000
CY2024Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
17554000
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
25573000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
62650000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
91029000
CY2024Q3 us-gaap Restructuring Charges
RestructuringCharges
18554000
CY2023Q3 us-gaap Restructuring Charges
RestructuringCharges
12606000
us-gaap Restructuring Charges
RestructuringCharges
18554000
us-gaap Restructuring Charges
RestructuringCharges
12606000
CY2024Q3 us-gaap Costs And Expenses
CostsAndExpenses
63111000
CY2023Q3 us-gaap Costs And Expenses
CostsAndExpenses
103616000
us-gaap Costs And Expenses
CostsAndExpenses
211637000
us-gaap Costs And Expenses
CostsAndExpenses
348234000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-16778000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-63482000
us-gaap Operating Income Loss
OperatingIncomeLoss
-58760000
us-gaap Operating Income Loss
OperatingIncomeLoss
-227620000
CY2024Q3 us-gaap Interest Expense
InterestExpense
4994000
CY2023Q3 us-gaap Interest Expense
InterestExpense
5022000
us-gaap Interest Expense
InterestExpense
14774000
us-gaap Interest Expense
InterestExpense
10464000
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3802000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4296000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5092000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
7984000
CY2024Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-1192000
CY2023Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-726000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-9682000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-2480000
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-17970000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-64208000
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-68442000
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-230100000
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
12000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
84000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-217000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-77000
CY2024Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
898000
CY2023Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
677000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
2664000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
2023000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-17084000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-63615000
us-gaap Net Income Loss
NetIncomeLoss
-65561000
us-gaap Net Income Loss
NetIncomeLoss
-228000000
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.17
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.17
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.65
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.65
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.66
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.66
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.35
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.35
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
100515000
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
100515000
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
98245000
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
98245000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
99780000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
99780000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
96901000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
96901000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-17084000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-63615000
us-gaap Net Income Loss
NetIncomeLoss
-65561000
us-gaap Net Income Loss
NetIncomeLoss
-228000000
CY2024Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1821000
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1033000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
1271000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-3618000
CY2024Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
2000
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
360000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-24000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
2415000
CY2024Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-1819000
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-673000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
1247000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-1203000
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-18903000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-64288000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-64314000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-229203000
CY2024Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-211853000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-17084000
CY2024Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
2000
CY2024Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1821000
CY2024Q3 fgen Adjustments To Additional Paid In Capital Shares Issued From Stock Plans Net Of Payroll Taxes Paid
AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid
-111000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7687000
CY2024Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-223180000
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-81787000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-63615000
CY2023Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
360000
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1033000
CY2023Q3 fgen Adjustments To Additional Paid In Capital Shares Issued From Stock Plans Net Of Payroll Taxes Paid
AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid
-83000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9476000
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-136682000
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-183679000
us-gaap Net Income Loss
NetIncomeLoss
-65561000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-24000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
1271000
fgen Adjustments To Additional Paid In Capital Shares Issued From Stock Plans Net Of Payroll Taxes Paid
AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid
-224000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
25037000
CY2024Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-223180000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-1480000
us-gaap Net Income Loss
NetIncomeLoss
-228000000
us-gaap Stock Issued During Period Shares Acquisitions
StockIssuedDuringPeriodSharesAcquisitions
520000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
2415000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-3618000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
48407000
fgen Adjustments To Additional Paid In Capital Shares Issued From Stock Plans Net Of Payroll Taxes Paid
AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid
3603000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
41471000
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-136682000
us-gaap Profit Loss
ProfitLoss
-65561000
us-gaap Profit Loss
ProfitLoss
-228000000
us-gaap Depreciation
Depreciation
2312000
us-gaap Depreciation
Depreciation
7653000
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
28000
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
402000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1680000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
3654000
fgen Investment Gain Loss In Unconsolidated Variable Interest Entity
InvestmentGainLossInUnconsolidatedVariableInterestEntity
2664000
fgen Investment Gain Loss In Unconsolidated Variable Interest Entity
InvestmentGainLossInUnconsolidatedVariableInterestEntity
2023000
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-2445000
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-1000
us-gaap Share Based Compensation
ShareBasedCompensation
25037000
us-gaap Share Based Compensation
ShareBasedCompensation
41471000
fgen Acquired In Process Research And Development Expenses
AcquiredInProcessResearchAndDevelopmentExpenses
0
fgen Acquired In Process Research And Development Expenses
AcquiredInProcessResearchAndDevelopmentExpenses
24636000
fgen Non Cash Change In Accrued Interest Expense And Payments Related To Sale Of Future Revenues
NonCashChangeInAccruedInterestExpenseAndPaymentsRelatedToSaleOfFutureRevenues
0
fgen Non Cash Change In Accrued Interest Expense And Payments Related To Sale Of Future Revenues
NonCashChangeInAccruedInterestExpenseAndPaymentsRelatedToSaleOfFutureRevenues
5636000
fgen Dividend Received From Unconsolidated Variable Interest Entity
DividendReceivedFromUnconsolidatedVariableInterestEntity
2230000
fgen Dividend Received From Unconsolidated Variable Interest Entity
DividendReceivedFromUnconsolidatedVariableInterestEntity
2255000
fgen Impairments Of Investments
ImpairmentsOfInvestments
0
fgen Impairments Of Investments
ImpairmentsOfInvestments
1000000
fgen Debt Securities Available For Sale Realized Gain Loss Excluding Other Than Temporary Impairments
DebtSecuritiesAvailableForSaleRealizedGainLossExcludingOtherThanTemporaryImpairments
0
fgen Debt Securities Available For Sale Realized Gain Loss Excluding Other Than Temporary Impairments
DebtSecuritiesAvailableForSaleRealizedGainLossExcludingOtherThanTemporaryImpairments
-271000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
15958000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
16283000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-17778000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1519000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
18181000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
27393000
fgen Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
-66011000
fgen Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
-8447000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-1115000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-962000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-8705000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-14057000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-17112000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-50246000
fgen Increase Decrease In Operating Lease Liabilities Current
IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent
-12796000
fgen Increase Decrease In Operating Lease Liabilities Current
IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent
1669000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-15218000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-36930000
fgen Increase Decrease In Accrued Interest Expense Related To Sale Of Future Revenues
IncreaseDecreaseInAccruedInterestExpenseRelatedToSaleOfFutureRevenues
115000
fgen Increase Decrease In Accrued Interest Expense Related To Sale Of Future Revenues
IncreaseDecreaseInAccruedInterestExpenseRelatedToSaleOfFutureRevenues
0
fgen Increase Decrease In Accrued Interest For Finance Lease Liabilities
IncreaseDecreaseInAccruedInterestForFinanceLeaseLiabilities
18000
fgen Increase Decrease In Accrued Interest For Finance Lease Liabilities
IncreaseDecreaseInAccruedInterestForFinanceLeaseLiabilities
-22000
fgen Increase Decrease In Operating Lease Liabilities Non Current
IncreaseDecreaseInOperatingLeaseLiabilitiesNonCurrent
-65830000
fgen Increase Decrease In Operating Lease Liabilities Non Current
IncreaseDecreaseInOperatingLeaseLiabilitiesNonCurrent
-9447000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-917000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-1529000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-107533000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-296700000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
125000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2268000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
840000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
8628000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
157210000
us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
0
us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
656000
fgen Proceeds From Sales Of Available For Sale Securities
ProceedsFromSalesOfAvailableForSaleSecurities
0
fgen Proceeds From Sales Of Available For Sale Securities
ProceedsFromSalesOfAvailableForSaleSecurities
1730000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
132183000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
300507000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
124270000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
143415000
us-gaap Proceeds From Issuance Of Secured Debt
ProceedsFromIssuanceOfSecuredDebt
0
us-gaap Proceeds From Issuance Of Secured Debt
ProceedsFromIssuanceOfSecuredDebt
74078000
us-gaap Repayments Of Secured Debt
RepaymentsOfSecuredDebt
0
us-gaap Repayments Of Secured Debt
RepaymentsOfSecuredDebt
2746000
fgen Repayments Of Finance Lease Liabilities
RepaymentsOfFinanceLeaseLiabilities
36000
fgen Repayments Of Finance Lease Liabilities
RepaymentsOfFinanceLeaseLiabilities
128000
us-gaap Repayments Of Debt And Capital Lease Obligations
RepaymentsOfDebtAndCapitalLeaseObligations
0
us-gaap Repayments Of Debt And Capital Lease Obligations
RepaymentsOfDebtAndCapitalLeaseObligations
302000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
340000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
0
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
0
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
48407000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
116000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3686000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-260000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
122995000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
838000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-4496000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
17315000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-34786000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
113688000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
155700000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
131003000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
120914000
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. The more significant areas requiring the use of management estimates and assumptions include valuation and recognition of revenue and deferred revenue, specifically, estimates in variable consideration for drug product sales, and estimates in transaction price per unit for the China performance obligation. On an ongoing basis, management reviews these estimates and assumptions. Changes in facts and circumstances may alter such estimates and actual results could differ from those estimates. In the Company’s opinion, the accompanying unaudited condensed consolidated financial statements include all normal recurring adjustments necessary for a fair statement of its financial position, results of operations and cash flows for the interim periods presented.</span></p>
CY2024Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
19147000
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
16448000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
18460000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13786000
us-gaap Lessee Operating Lease Option To Terminate
LesseeOperatingLeaseOptionToTerminate
As part of its continuing efforts to reduce operating expenses and preserve cash, on September 27, 2024, the Company entered into an Agreement for Termination of Lease and Voluntary Surrender of Premises (“Lease Termination Agreement”) with its landlord, ARE-San Francisco No.43 Owner, LLC (“ARE”) related to the Company’s operating lease of its corporate headquarters in San Francisco, California. The Lease Termination Agreement modifies the lease agreement dated as of September 22, 2006, as subsequently amended and accelerates the expiration date of the term of the Lease from 2028 to no later than December 31, 2024.
us-gaap Lessee Operating Lease Existence Of Option To Terminate
LesseeOperatingLeaseExistenceOfOptionToTerminate
true
CY2024Q3 fgen Lease Termination Settlement Amount
LeaseTerminationSettlementAmount
10000000
CY2024Q3 fgen Lease Termination Settlement Amount One Time Payment
LeaseTerminationSettlementAmountOneTimePayment
8300000
CY2024Q3 us-gaap Line Of Credit
LineOfCredit
1700000
CY2024Q3 us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
1700000
CY2024Q3 fgen Fair Value Assets Level2 To Level1 Transfer Amount
FairValueAssetsLevel2ToLevel1TransferAmount
0
CY2024Q3 fgen Fair Value Assets Level1 To Level2 Transfer Amount
FairValueAssetsLevel1ToLevel2TransferAmount
0
CY2024Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2024Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2024Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2024Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2024Q1 fgen Fair Value Of Us Treasury Notes And Bills Transfered From Level One To Level Two1
FairValueOfUsTreasuryNotesAndBillsTransferedFromLevelOneToLevelTwo1
26300000
CY2024Q3 us-gaap Cash
Cash
56176000
CY2023Q4 us-gaap Cash
Cash
63396000
CY2024Q3 us-gaap Commercial Paper At Carrying Value
CommercialPaperAtCarryingValue
25631000
CY2023Q4 us-gaap Commercial Paper At Carrying Value
CommercialPaperAtCarryingValue
36016000
CY2024Q3 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
49196000
CY2023Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
12288000
CY2024Q3 us-gaap Us Government Securities At Carrying Value
USGovernmentSecuritiesAtCarryingValue
0
CY2023Q4 us-gaap Us Government Securities At Carrying Value
USGovernmentSecuritiesAtCarryingValue
1988000
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
131003000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
113688000
CY2024Q3 us-gaap Short Term Investments
ShortTermInvestments
0
CY2024Q3 us-gaap Long Term Investments
LongTermInvestments
0
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
121874000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
30000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
6000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
121898000
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
9971000
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
1000
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
3495000
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
5000
CY2023Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
13466000
CY2023Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
6000
CY2024Q3 fgen Impairment Loss On Debt Securities Available For Sale
ImpairmentLossOnDebtSecuritiesAvailableForSale
0
CY2023Q3 fgen Impairment Loss On Debt Securities Available For Sale
ImpairmentLossOnDebtSecuritiesAvailableForSale
0
fgen Impairment Loss On Debt Securities Available For Sale
ImpairmentLossOnDebtSecuritiesAvailableForSale
0
CY2023Q3 fgen Impairment Loss On Debt Securities Available For Sale
ImpairmentLossOnDebtSecuritiesAvailableForSale
0
CY2024Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
948000
CY2023Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
1376000
CY2024Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
17775000
CY2023Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
34614000
CY2024Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
5214000
CY2023Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
5575000
CY2024Q3 us-gaap Inventory Net
InventoryNet
23937000
CY2023Q4 us-gaap Inventory Net
InventoryNet
41565000
CY2024Q3 us-gaap Supplies
Supplies
25804000
CY2023Q4 us-gaap Supplies
Supplies
26481000
CY2024Q3 fgen Deferred Revenues From Associated Contracts
DeferredRevenuesFromAssociatedContracts
0
CY2023Q4 fgen Deferred Revenues From Associated Contracts
DeferredRevenuesFromAssociatedContracts
-26481000
CY2024Q3 fgen Supplies Net
SuppliesNet
25804000
CY2023Q4 fgen Supplies Net
SuppliesNet
0
CY2024Q3 us-gaap Loss Contingency Receivable Current
LossContingencyReceivableCurrent
28500000
CY2023Q4 us-gaap Loss Contingency Receivable Current
LossContingencyReceivableCurrent
28500000
CY2024Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
3062000
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
6644000
CY2024Q3 us-gaap Other Assets Current
OtherAssetsCurrent
3193000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
6711000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
60559000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
41855000
CY2024Q3 us-gaap Loss Contingency Receivable Current
LossContingencyReceivableCurrent
28500000
CY2023Q4 us-gaap Loss Contingency Receivable Current
LossContingencyReceivableCurrent
28500000
CY2024Q3 fgen Accrued Preclinical And Clinical Trial Current
AccruedPreclinicalAndClinicalTrialCurrent
6689000
CY2023Q4 fgen Accrued Preclinical And Clinical Trial Current
AccruedPreclinicalAndClinicalTrialCurrent
27663000
CY2024Q3 fgen Accrued Api And Bulk Drug Product Price True Up Current
AccruedApiAndBulkDrugProductPriceTrueUpCurrent
12592000
CY2023Q4 fgen Accrued Api And Bulk Drug Product Price True Up Current
AccruedApiAndBulkDrugProductPriceTrueUpCurrent
50978000
CY2024Q3 fgen Litigation Settlement Current
LitigationSettlementCurrent
28500000
CY2023Q4 fgen Litigation Settlement Current
LitigationSettlementCurrent
28500000
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6144000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
20267000
CY2024Q3 fgen Accrued Restructuring Charge Current
AccruedRestructuringChargeCurrent
14173000
CY2023Q4 fgen Accrued Restructuring Charge Current
AccruedRestructuringChargeCurrent
3697000
CY2024Q3 fgen Accrued Inventory Cost
AccruedInventoryCost
8521000
CY2024Q3 fgen Accrued Co Promotion Expenses Current
AccruedCoPromotionExpensesCurrent
53714000
CY2023Q4 fgen Accrued Co Promotion Expenses Current
AccruedCoPromotionExpensesCurrent
10309000
CY2023Q4 fgen Accrued Profit Share Current
AccruedProfitShareCurrent
7084000
CY2024Q3 fgen Lease Termination Related
LeaseTerminationRelated
4558000
CY2024Q3 us-gaap Accrual For Taxes Other Than Income Taxes Current
AccrualForTaxesOtherThanIncomeTaxesCurrent
7121000
CY2023Q4 us-gaap Accrual For Taxes Other Than Income Taxes Current
AccrualForTaxesOtherThanIncomeTaxesCurrent
6615000
CY2024Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
4396000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
7103000
CY2024Q3 fgen Liability Related To Sale Of Future Revenues Current
LiabilityRelatedToSaleOfFutureRevenuesCurrent
332000
CY2023Q4 fgen Liability Related To Sale Of Future Revenues Current
LiabilityRelatedToSaleOfFutureRevenuesCurrent
5654000
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
4401000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
5021000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
151141000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
172891000
CY2024Q3 fgen Accrued Api And Bulk Drug Product Price True Up Current
AccruedApiAndBulkDrugProductPriceTrueUpCurrent
12600000
CY2023Q4 fgen Accrued Api And Bulk Drug Product Price True Up Current
AccruedApiAndBulkDrugProductPriceTrueUpCurrent
51000000
CY2024Q3 fgen Accrued Litigation Settlement
AccruedLitigationSettlement
28500000
CY2023Q4 fgen Accrued Litigation Settlement
AccruedLitigationSettlement
28500000
CY2024Q3 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.75
us-gaap Restructuring Charges
RestructuringCharges
18600000
us-gaap Payments For Restructuring
PaymentsForRestructuring
6100000
CY2024Q3 fgen Accrued Restructuring Charges
AccruedRestructuringCharges
14200000
CY2024Q3 fgen Accrued Inventory Cost
AccruedInventoryCost
8500000
CY2024Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
2900000
us-gaap Interest Expense Debt
InterestExpenseDebt
8700000
CY2023Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
2900000
us-gaap Interest Expense Debt
InterestExpenseDebt
4500000
CY2024Q3 fgen Debt Instrument Accrued Interest
DebtInstrumentAccruedInterest
400000
CY2023Q4 fgen Liability Related To Sale Of Future Revenues
LiabilityRelatedToSaleOfFutureRevenues
57067000
fgen Interest Paid Related To Sale Of Future Revenues
InterestPaidRelatedToSaleOfFutureRevenues
-5653000
fgen Non Cash Interest Expense Related To Sale Of Future Revenues
NonCashInterestExpenseRelatedToSaleOfFutureRevenues
5768000
CY2024Q3 fgen Liability Related To Sale Of Future Revenues
LiabilityRelatedToSaleOfFutureRevenues
57182000
fgen Liability Related To Sale Of Revenue Current
LiabilityRelatedToSaleOfRevenueCurrent
332000
fgen Liability Related To Sale Of Revenues Noncurrent
LiabilityRelatedToSaleOfRevenuesNoncurrent
56850000
CY2024Q1 fgen Interest Paid Related To Sale Of Future Revenues
InterestPaidRelatedToSaleOfFutureRevenues
-5700000
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
2000000
CY2021Q2 us-gaap Loss Contingency New Claims Filed Number
LossContingencyNewClaimsFiledNumber
5
CY2023Q4 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
28500000
CY2023Q4 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
28500000
us-gaap Loss Contingency New Claims Filed Number
LossContingencyNewClaimsFiledNumber
7
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-24-125388-index-headers.html Edgar Link pending
0000950170-24-125388-index.html Edgar Link pending
0000950170-24-125388.txt Edgar Link pending
0000950170-24-125388-xbrl.zip Edgar Link pending
fgen-20240930.htm Edgar Link pending
fgen-20240930.xsd Edgar Link pending
fgen-ex31_1.htm Edgar Link pending
fgen-ex31_2.htm Edgar Link pending
fgen-ex32_1.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
fgen-20240930_htm.xml Edgar Link completed
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending